Who
Elvia Cowan
SVP, Finance & CAO
Company insider
Files Form 4 as: SVP, Finance & CAO, Vaxcyte.
In numbers
- Trades disclosed
- 75
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $5.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Mar 2023
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $492K19,000 at $25.92 | filing |
| 5 Oct 2026filed 7 Oct 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $1.6M19,000 at $86.74 | filing |
| 5 Oct 2026filed 7 Oct 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,000 at $0.00 | filing |
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $80K1,327 at $60.36 | filing |
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $80K1,327 at $60.36 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $20K326 at $61.58 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $20K326 at $61.58 | filing |
| 31 Aug 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $15K243 at $60.74 | filing |
| 31 Aug 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $15K243 at $60.74 | filing |
| 7 Apr 2026filed 8 Apr 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $78K3,000 at $25.92 | filing |
| 7 Apr 2026filed 8 Apr 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $180K3,000 at $60.00 | filing |
| 7 Apr 2026filed 8 Apr 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 7 Apr 2026filed 8 Apr 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 7 Apr 2026filed 8 Apr 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $78K3,000 at $25.92 | filing |
| 7 Apr 2026filed 8 Apr 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $180K3,000 at $60.00 | filing |
| 17 Mar 2026filed 18 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $82K1,487 at $55.39 | filing |
| 17 Mar 2026filed 18 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $23K405 at $56.26 | filing |
| 17 Mar 2026filed 18 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $82K1,487 at $55.39 | filing |
| 17 Mar 2026filed 18 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $23K405 at $56.26 | filing |
| 11 Mar 2026filed 11 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $65K2,500 at $25.92 | filing |
News
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesPCVX · rttnews.com · 16 Oct 2026Vaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor FitzgeraldPCVX · dailypolitical.com · 13 Oct 2026Vaxcyte (NASDAQ:PCVX) Sees Large Volume Increase on Analyst UpgradePCVX · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Elvia Cowan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.